Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia
The investigators adopted the CAMS（Chinese Academy of Medical Sciences）-2009 trial for pediatric acute myeloid leukemia (AML) patients between 2009 to 2015, in which a risk-stratified strategy and dose-dense intensive chemotherapy were introduced. The outcomes of CAMS-2009 trial were retrospectively analyzed, and compared to the CAMS-2005 trial.
Acute Myeloid Leukemia, Pediatric
OTHER: Risk-stratified therapy
overall survival (OS), overall survival, From date of diagnosed until the date of death from any cause, assessed up to 60 months|event-free survival (EFS), event-free survival, From date of diagnosed until the date of first relapse or date of death from any cause, whichever came first, assessed up to 60 months|complete remission (CR), fewer than 5% blast cells in the bone marrow aspirate and the absence of extramedullary involvement (EMI), through study completion, an average of 1 year
The investigators adopted the CAMS（Chinese Academy of Medical Sciences）-2009 trial for pediatric acute myeloid leukemia (AML) patients between 2009 to 2015, in which a risk-stratified strategy and dose-dense intensive chemotherapy were introduced. The outcomes of CAMS-2009 trial were retrospectively analyzed, and compared to the CAMS-2005 trial.